Navigation Links
Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Date:3/26/2013

HAYWARD, Calif., March 26, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter and fiscal year ended December 31, 2012.

Fourth Quarter and Fiscal Year 2012 Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2012 were $8.1 million, as compared to $11.1 million for the third quarter ended September 30, 2012. The decrease in operating expenses for the period is related primarily to the reduced clinical activity following the completion of the PEARL-SC study.

Total operating expenses for the fiscal year ended December 31, 2012 were $55.9 million, as compared to $93.1 million for the fiscal year ended December 31, 2011. The decrease in operating expenses for the period can be attributed to the reduced clinical activity following the completion of the PEARL-SC study and the termination of the VISTA-16 study in early 2012.  

Anthera ended the fourth quarter of 2012 with approximately $24.8 million in cash and cash equivalents and short-term investments. On January 30, 2013, the Company completed a public offering of shares of its common stock resulting in net proceeds of approximately $43.0 million from the sale of 69,696,970 shares, which includes 9,090,909 shares issued upon the exercise in full of the underwriters' over-allotment option.

The Company intends to host a conference call during the second quarter of 2013 to provide an update on the Company's clinical development plan.

Recent Management Update:

Sanford Zweifach has been appointed to Anthera's Board of Directors.  Mr. Zweifach has over 20 years of extensive experience in the areas of corporate partnering, business development, operational and P&L experience, private and public investing and capital-raising in the life sciences industry. He currently serves as the Chief Executive Officer of Ascendancy Healthcare, Inc.  From 2005 until mid-2011, Mr. Zweifach was a Partner at Reedland Capital Partners, a boutique investment bank, where he headed its life sciences M&A and advisory efforts. Prior to joining Reedland, he was the CEO of Pathways Diagnostics, a biomarker development company. From 1997 to 2004 he was a Managing Director/CFO of Bay City Capital.  He received his BA in Biology from UC San Diego and holds an MS in Human Physiology from UC Davis.

"I am excited to welcome Sandy to the Anthera Board of Directors," said Dr. Christopher Henney , Ph.D., Anthera's Chairman of the Board. "His extensive expertise in commercial development and pharmaceutical transactions will be invaluable as we continue to move forward with the development of blisibimod."

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)(in thousands except share and per share data)Three Months Ended Dec 31,Twelve Months Ended Dec 31,2012201120122011OPERATING EXPENSE:  Research and development

$
7,089$
26,832$
49,219$
85,281  General and administrative

1,0001,5976,7157,857Total operating expense

8,08928,42955,93493,138LOSS FROM OPERATIONS:

(8,089)(28,429)(55,934)(93,138)OTHER (EXPENSE)/INCOME:Other (expense) income

(27)185(111)606Interest expense

(797)(912)(3,354)(2,803)Total other income (expense)

(824)(727)(3,465)(2,197)NET LOSS

$  (8,913)$   (29,156)$  (59,399)$   (95,335)Net loss per share--basic and diluted

$
(0.11)$
(0.71)$
(1.03)$
(2.55) Weighted-average number of shares used in per share calculation-- basic and diluted

79,120,94040,916,66657,803,49137,417,775 

 ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)December 31,
2012December 31,
2011Cash and cash equivalents

$
9,431$
5,624Short term investments

$
5,322$
,746Total assets

$
26,445$
9,493Total current liabilities, excluding current portion of notes payable

$
9,421$
26,078Total notes payable

$
20,550$
24,331Deficit accumulated during development stage

$  (260,378)$  (200,979)Total shareholders' equity(deficit)

$
(3,526)$
9,084Common shares outstanding

79,151,59240,933,354 


'/>"/>
SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
2. Anthera to Report Second Quarter 2012 Financial Results
3. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
7. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
8. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
9. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):